New News information at Pharmaceutical Technology New and updated information from News listed on www.pharmaceutical-technology.com http://www.pharmaceutical-technology.com/ en-us http://www.pharmaceutical-technology.com/ New News information at Pharmaceutical Technology http://www.pharmaceutical-technology.com/content/images/logo_big.gif ICR scientists uncover information about genetic causes of brain cancer http://www.pharmaceutical-technology.com/news/newsicr-scientists-uncover-information-about-genetic-causes-of-brain-cancer-5773001 http://www.pharmaceutical-technology.com/news/newsicr-scientists-uncover-information-about-genetic-causes-of-brain-cancer-5773001 A new brain cancer study conducted by scientists at London's Institute of Cancer Research (ICR) has revealed new secrets about the genetic causes of the disease. Mon, 27 Mar 2017 23:00:00 GMT Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn http://www.pharmaceutical-technology.com/news/newsperrigo-completes-sale-of-tysabri-drug-royalty-to-rpi-for-285bn-5773018 http://www.pharmaceutical-technology.com/news/newsperrigo-completes-sale-of-tysabri-drug-royalty-to-rpi-for-285bn-5773018 Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn. Mon, 27 Mar 2017 23:00:00 GMT EC approves Pfizer's Xeljanz to treat rheumatoid arthritis in EU http://www.pharmaceutical-technology.com/news/newsec-approves-pfizers-xeljanz-to-treat-rheumatoid-arthritis-in-eu-5772967 http://www.pharmaceutical-technology.com/news/newsec-approves-pfizers-xeljanz-to-treat-rheumatoid-arthritis-in-eu-5772967 The European Commission (EC) has approved Pfizer's Xeljanz (tofacitinib citrate) oral tablets to treat moderate-to-severe active rheumatoid arthritis (RA) in adult patients in the European Union (EU). Mon, 27 Mar 2017 23:00:00 GMT Leukaemia CARE’s research finds inequalities in cancer care for elderly patients http://www.pharmaceutical-technology.com/news/newsleukaemia-cares-research-finds-inequalities-in-cancer-care-for-elderly-patients-5771943 http://www.pharmaceutical-technology.com/news/newsleukaemia-cares-research-finds-inequalities-in-cancer-care-for-elderly-patients-5771943 UK charity Leukaemia CARE has conducted new research into the lives of older people living with blood cancers and revealed inequalities in cancer care for elderly patients compared with those who are younger. Sun, 26 Mar 2017 23:00:00 GMT PureTech Health and Novartis to advance clinical-stage programmes http://www.pharmaceutical-technology.com/news/newspuretech-health-novartis-to-advance-clinical-stage-programmes-5771917 http://www.pharmaceutical-technology.com/news/newspuretech-health-novartis-to-advance-clinical-stage-programmes-5771917 US-based PureTech Health has signed a licensing and equity agreement with Swiss company Novartis to advance two clinical-stage programmes targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway. Sun, 26 Mar 2017 23:00:00 GMT Merck and Pfizer secure US FDA approval for Bavencio to treat skin cancer http://www.pharmaceutical-technology.com/news/newsmerck-pfizer-secure-us-fda-approval-for-bavencio-to-treat-skin-cancer-5771929 http://www.pharmaceutical-technology.com/news/newsmerck-pfizer-secure-us-fda-approval-for-bavencio-to-treat-skin-cancer-5771929 Merck’s biopharmaceutical business EMD Serono and Pfizer have obtained the US Food and Drug Administration’s (FDA) approval for a 20mg/mL Bavencio (avelumab) injection to treat patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggress… Sun, 26 Mar 2017 23:00:00 GMT M&As this week: Sun Moral International (HK), Immuno Holding http://www.pharmaceutical-technology.com/news/newsmas-this-week-sun-moral-international-hk-ltd-immuno-holding-sa-de-cv-5770731 http://www.pharmaceutical-technology.com/news/newsmas-this-week-sun-moral-international-hk-ltd-immuno-holding-sa-de-cv-5770731 Sun Moral International (HK), a subsidiary of Chinese pharmaceutical company Sihuan Pharmaceutical Holdings Group, has acquired the entire equity interest in Ambest Pharmaceutical (China) Company. Fri, 24 Mar 2017 00:00:00 GMT Cancer Research UK to support Precision Panc project for pancreatic cancer http://www.pharmaceutical-technology.com/news/newscancer-research-uk-to-support-precision-panc-project-for-pancreatic-cancer-5770984 http://www.pharmaceutical-technology.com/news/newscancer-research-uk-to-support-precision-panc-project-for-pancreatic-cancer-5770984 Cancer Research UK has announced an investment of £10m to support the Precision Panc project, which aims to develop personalised treatments for pancreatic cancer patients. Fri, 24 Mar 2017 00:00:00 GMT Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG http://www.pharmaceutical-technology.com/news/newsalexion-submits-application-to-japans-mhlw-to-extend-soliris-indication-to-treat-gmg-5770960 http://www.pharmaceutical-technology.com/news/newsalexion-submits-application-to-japans-mhlw-to-extend-soliris-indication-to-treat-gmg-5770960 Alexion Pharmaceuticals has submitted an application to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalised myasthenia gravis (gMG). Fri, 24 Mar 2017 00:00:00 GMT RGC, UK Biobank and GSK launch new initiative to improve disease diagnosis http://www.pharmaceutical-technology.com/news/newsrgc-uk-biobank-and-gsk-launch-new-initiative-to-improve-disease-diagnosis-5770968 http://www.pharmaceutical-technology.com/news/newsrgc-uk-biobank-and-gsk-launch-new-initiative-to-improve-disease-diagnosis-5770968 Regeneron Genetics Center (RGC), UK Biobank and GSK have launched a gene sequencing initiative on the world's detailed health database. Fri, 24 Mar 2017 00:00:00 GMT Deals this week: Ascend Therapeutics US, Tyme Technologies, Axsome Therapeutics http://www.pharmaceutical-technology.com/news/newsdeals-this-week-ascend-therapeutics-us-llc-tyme-technologies-inc-axsome-therapeutics-inc-5770644 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-ascend-therapeutics-us-llc-tyme-technologies-inc-axsome-therapeutics-inc-5770644 Ascend Therapeutics US will be the exclusive seller and marketer of Aevum Life Science’s Protiva Pregnancy and Protiva New Mom / Recover products across the US, under an agreement signed between the two companies. Fri, 24 Mar 2017 00:00:00 GMT US FDA grants Fast Track designation for Shire’s SHP655 http://www.pharmaceutical-technology.com/news/newsus-fda-grants-fast-track-designation-for-shires-shp655-5769697 http://www.pharmaceutical-technology.com/news/newsus-fda-grants-fast-track-designation-for-shires-shp655-5769697 The US Food and Drug Administration (FDA) has granted Fast Track designation for Shire’s recombinant ADAMTS13 (SHP655 or previously known as BAX930) to treat acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP). Thu, 23 Mar 2017 00:00:00 GMT British Columbia to provide public access to Gilead Sciences’ Epclusa for genotype 1-6 HCV http://www.pharmaceutical-technology.com/news/newsbc-to-provide-public-access-to-gilead-sciences-epclusa-for-genotype-1-6-hcv-5769723 http://www.pharmaceutical-technology.com/news/newsbc-to-provide-public-access-to-gilead-sciences-epclusa-for-genotype-1-6-hcv-5769723 British Columbia (BC) has listed Gilead Sciences Canada’s Epclusa (sofosbuvir / velpatasvir) tablets on a public drug plan to treat all six genotypes of chronic hepatitis C virus (HCV) infection. Thu, 23 Mar 2017 00:00:00 GMT Argenx and Broteio Pharma partner to develop antibody for autoimmune diseases http://www.pharmaceutical-technology.com/news/newsargenx-broteio-pharma-partner-to-develop-antibody-for-autoimmune-diseases-5769709 http://www.pharmaceutical-technology.com/news/newsargenx-broteio-pharma-partner-to-develop-antibody-for-autoimmune-diseases-5769709 Netherlands-based biotechnology company argenx and Broteio Pharma, a joint venture between Prothix and Bioceros, have agreed to partner for the development of a therapeutic antibody for severe autoimmune diseases. Thu, 23 Mar 2017 00:00:00 GMT US FDA approves Xadago to treat patients with Parkinson’s disease http://www.pharmaceutical-technology.com/news/newsus-fda-approves-xadago-to-treat-patients-with-parkinsons-disease-5768749 http://www.pharmaceutical-technology.com/news/newsus-fda-approves-xadago-to-treat-patients-with-parkinsons-disease-5768749 The US Food and Drug Administration (FDA) has approved Newron Pharmaceuticals’ Xadago (safinamide) tablets to treat patients with Parkinson’s disease. Wed, 22 Mar 2017 00:00:00 GMT Pierre Fabre and H-Immune to develop new cancer immunotherapies http://www.pharmaceutical-technology.com/news/newspierre-fabre-h-immune-to-develop-new-cancer-immunotherapies-5768739 http://www.pharmaceutical-technology.com/news/newspierre-fabre-h-immune-to-develop-new-cancer-immunotherapies-5768739 French pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop new cancer immunotherapies. Wed, 22 Mar 2017 00:00:00 GMT Ferrier Research Institute and BCFNZ to create new breast cancer vaccine http://www.pharmaceutical-technology.com/news/newsferrier-research-institute-and-bcfnz-to-create-new-breast-cancer-vaccine-5768721 http://www.pharmaceutical-technology.com/news/newsferrier-research-institute-and-bcfnz-to-create-new-breast-cancer-vaccine-5768721 Victoria University of Wellington's Ferrier Research Institute and the Breast Cancer Foundation New Zealand (BCFNZ) have joined forces to create a new vaccine for breast cancer. Wed, 22 Mar 2017 00:00:00 GMT Emergent signs $100m BARDA contract to deliver BioThrax http://www.pharmaceutical-technology.com/news/newsemergent-signs-100m-barda-contract-to-deliver-biothrax-5767830 http://www.pharmaceutical-technology.com/news/newsemergent-signs-100m-barda-contract-to-deliver-biothrax-5767830 US-based Emergent BioSolutions has signed a $100m contract with the Biomedical Advanced Research and Development Authority (BARDA) to deliver BioThrax (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS). Tue, 21 Mar 2017 00:00:00 GMT PCC acquires Intrathecal Therapy business from Mallinckrodt for $203m http://www.pharmaceutical-technology.com/news/newspcc-acquires-intrathecal-therapy-business-from-mallinckrodt-for-203m-5767837 http://www.pharmaceutical-technology.com/news/newspcc-acquires-intrathecal-therapy-business-from-mallinckrodt-for-203m-5767837 Piramal’s wholly owned Critical Care subsidiary in the UK PCC has completed its previously announced acquisition of Intrathecal Therapy business from Mallinckrodt for $203m. Tue, 21 Mar 2017 00:00:00 GMT CannRx and iCAN:Israel-Cannabis form JV to launch sleep cannabis formulation http://www.pharmaceutical-technology.com/news/newscannrx-icanisrael-cannabis-form-jv-to-launch-sleep-cannabis-formulation-5767859 http://www.pharmaceutical-technology.com/news/newscannrx-icanisrael-cannabis-form-jv-to-launch-sleep-cannabis-formulation-5767859 CannRx Technologies and iCAN:Israel-Cannabis have announced the formation of a joint venture (JV) in a bid to market ican.sleep, the sleep cannabis formulation. Tue, 21 Mar 2017 00:00:00 GMT